Host: Jhanelle E. Gray, MD Guest: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Joshua E. Reuss, MD Guest: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Jhanelle E. Gray, MD Guest: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectiv…

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectiv…

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectiv…

Host: Javier Cortes, MD, PhD Guest: Komal Jhaveri, MD, FACP The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optima…

Host: Marianna Fontana, MD Guest: Ronald Witteles, MD Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoi…

Host: Arshad M. Khanani, MD, MA Guest: Karl Csaky, MD, PhD Guest: Christina Y. Weng, MD, MBA, FASRS Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now avai…

Host: Craig M. McDonald, MD Guest: Crystal Proud, MD Guest: Aravindhan Veerapandiyan, MD There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoratio…

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

Host: Daniel Gaudet, MD, PhD This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.…

Host: Marc P. Bonaca, MD, MPH This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all…

Host: Marc P. Bonaca, MD, MPH This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all…

Host: Manesh R. Patel, MD This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.…

Host: Manesh R. Patel, MD This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.…

Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…

Host: Sara M. Tolaney, MD, MPH The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (e…

Host: Jennifer I. Lim, MD, FARVO Guest: Carl Regillo, MD What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with …

Guest: Vallerie V. McLaughlin, MD Host: Melisa A. Wilson, DNP, APRN, ACNP, BC Host: Sarah Kesler, MD Learn how to use guideline recommendations to establish a diagnosis of pulmonary arterial hypertension (PAH), develop evidence-based individualized treatment plans, and explore innovative therapies under investigation for PAH management. Hear from e…

Host: David Lynch, MB, BCh Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.

Host: Pietro A. Canetta, MD Expert Nephrologist Pietro Canetta, MD, MS, gives an overview of top abstracts from Kidney Week 2023 and new therapies for IgAN.

Host: Daniel Bessesen, MD Guest: Joanna Miragaya Guest: Jaime Almandoz, MD, MBA, FTOS Gain experts’ insights and tools for endocrinology specialists to use to support and empower community-based colleagues in successful and sustainable obesity management practices.

Host: Mario E. Lacouture, MD Host: Sapna Patel, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable mel…

Host: Mario E. Lacouture, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…

Host: Sapna Patel, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…

Host: Jeffrey S. Weber, MD, PhD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…

Host: Sapna Patel, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…

Host: Jeffrey S. Weber, MD, PhD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…

Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…

Host: Allison Betof Warner, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…